AIMS: Bundle branch block (BBB) early during acute myocardial infarction (AMI) is often considered high risk for mortality. Little is known about how different BBB types influence prognosis. METHODS AND RESULTS: The HERO-2 trial recruited 17 073 patients with ischaemic symptoms lasting >30 min and either ST elevation with or without right bundle branch block (RBBB) or presumed-new left bundle branch block (LBBB). Electrocardiograms were performed before and 60 min after the start of fibrinolytic therapy. Using patients with normal intraventricular conduction as a reference, odds ratios (ORs) for 30-day mortality were calculated for different BBB types (LBBB, RBBB with anterior AMI, and RBBB with inferior AMI) present at randomization and/or 60 min, with adjustment for recruitment region, pre-infarction characteristics, time to randomization, hemodynamics, and Killip class. At randomization, the 873 patients (5.11%) with BBB had worse baseline characteristics than patients without BBB. In patients presenting with LBBB (n=300), the ORs for 30-day mortality were 1.90 (95% CI 1.39-2.59) before and 0.68 (0.48-0.99) after adjustment for other prognosticators. In patients presenting with RBBB (n=415) and anterior AMI, the ORs were 3.52 (2.82-4.38) before and 2.48 (1.93-3.19) after adjustment. In patients presenting with RBBB and inferior AMI (n=158), the ORs were 1.74 (1.06-2.86) before and 1.22 (0.71-2.08) after adjustment. Within 60 min, 143 patients (0.92%) developed new BBB. The adjusted ORs for 30-day mortality were 2.97 (1.16-7.57) in the 25 patients with new LBBB, 3.84 (2.38-6.22) in the 100 with new RBBB and anterior AMI, and 2.23 (0.54-9.21) in the 18 with new RBBB and inferior AMI. CONCLUSION:RBBB accompanying anterior AMI at presentation and new BBB (including LBBB) early after fibrinolytic therapy are independent predictors of high 30-day mortality. These electrocardiographic features should be considered in risk stratification to identify high-risk patients.
RCT Entities:
AIMS: Bundle branch block (BBB) early during acute myocardial infarction (AMI) is often considered high risk for mortality. Little is known about how different BBB types influence prognosis. METHODS AND RESULTS: The HERO-2 trial recruited 17 073 patients with ischaemic symptoms lasting >30 min and either ST elevation with or without right bundle branch block (RBBB) or presumed-new left bundle branch block (LBBB). Electrocardiograms were performed before and 60 min after the start of fibrinolytic therapy. Using patients with normal intraventricular conduction as a reference, odds ratios (ORs) for 30-day mortality were calculated for different BBB types (LBBB, RBBB with anterior AMI, and RBBB with inferior AMI) present at randomization and/or 60 min, with adjustment for recruitment region, pre-infarction characteristics, time to randomization, hemodynamics, and Killip class. At randomization, the 873 patients (5.11%) with BBB had worse baseline characteristics than patients without BBB. In patients presenting with LBBB (n=300), the ORs for 30-day mortality were 1.90 (95% CI 1.39-2.59) before and 0.68 (0.48-0.99) after adjustment for other prognosticators. In patients presenting with RBBB (n=415) and anterior AMI, the ORs were 3.52 (2.82-4.38) before and 2.48 (1.93-3.19) after adjustment. In patients presenting with RBBB and inferior AMI (n=158), the ORs were 1.74 (1.06-2.86) before and 1.22 (0.71-2.08) after adjustment. Within 60 min, 143 patients (0.92%) developed new BBB. The adjusted ORs for 30-day mortality were 2.97 (1.16-7.57) in the 25 patients with new LBBB, 3.84 (2.38-6.22) in the 100 with new RBBB and anterior AMI, and 2.23 (0.54-9.21) in the 18 with new RBBB and inferior AMI. CONCLUSION: RBBB accompanying anterior AMI at presentation and new BBB (including LBBB) early after fibrinolytic therapy are independent predictors of high 30-day mortality. These electrocardiographic features should be considered in risk stratification to identify high-risk patients.
Authors: Cheuk-Kit Wong; Wanzhen Gao; Ralph A H Stewart; Jocelyne Benatar; John K French; Philip E G Aylward; Harvey D White Journal: Eur Heart J Date: 2010-05-31 Impact factor: 29.983
Authors: Matthew G Whitbeck; Richard J Charnigo; Jignesh Shah; Gustavo Morales; Steve W Leung; Brandon Fornwalt; Alison L Bailey; Khaled Ziada; Vincent L Sorrell; Milagros M Zegarra; Jenks Thompson; Neil Aboul Hosn; Charles L Campbell; John Gurley; Paul Anaya; David C Booth; Luigi Di Biase; Andrea Natale; Susan Smyth; David J Moliterno; Claude S Elayi Journal: Europace Date: 2013-12-23 Impact factor: 5.214
Authors: Harvey D White; Cheuk-Kit Wong; Wanzhen Gao; Aaron Lin; Jocelyne Benatar; Philip Eg Aylward; John K French; Ralph A Stewart Journal: Eur Heart J Acute Cardiovasc Care Date: 2012-09
Authors: Saraschandra Vallabhajosyula; Sri Harsha Patlolla; Dhiran Verghese; Lina Ya'Qoub; Vinayak Kumar; Anna V Subramaniam; Wisit Cheungpasitporn; Pranathi R Sundaragiri; Peter A Noseworthy; Siva K Mulpuru; Malcolm R Bell; Bernard J Gersh; Abhishek J Deshmukh Journal: Am J Cardiol Date: 2020-04-06 Impact factor: 2.778
Authors: Jacob Thorsted Sørensen; Carsten Stengaard; Christina Ankjær Sørensen; Kristian Thygesen; Hans Erik Bøtker; Leif Thuesen; Christian Juhl Terkelsen Journal: Eur Heart J Acute Cardiovasc Care Date: 2013-06